Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from Daito Pharmaceutical Co.,Ltd. was processed by Pulse News Wire on April 1, 2026. It represents a primary source document for Japanese Buyback sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
TOKYO, Apr 01 (Pulse News Wire) – Daito Pharmaceutical Co., Ltd. (4577.T) announced progress on its share repurchase program. The company acquired 208,800 shares for a total of ¥305,442,800 through op
View all Daito Pharmaceutical Co.,Ltd. disclosures →
Daito Pharmaceutical Co.,Ltd. [4577.T]
TOKYO, Apr 01 (Pulse News Wire) – Daito Pharmaceutical Co., Ltd. (4577.T) announced progress on its share repurchase program.
The company acquired 208,800 shares for a total of ¥305,442,800 through open market purchases. The board authorized the repurchase of up to 1,000,000 shares with a maximum expenditure of ¥1,500,000,000.
The program is 88.3% complete with 883,200 shares acquired to date.
🟢 Confidence: High AI-translated content.